The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. A phase 2, randomized, double-blind, dose-response study.

Trial Profile

The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. A phase 2, randomized, double-blind, dose-response study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2014

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 14 Jan 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 14 Jan 2009.
    • 30 Sep 2008 Actual patients number added 274 as reported by ClinicalTrials.gov.
    • 30 Sep 2008 Planned end date (1 Sep 2003) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top